mProX™ Human BMPR2 Stable Cell Line

Sub Cat	Product Name	Target Protein Species	Host Cell Type	Assay Types	Inquiry	Datasheet
S01YF-1122-KX1038	Magic™ Human BMPR2 in Vitro Assay	Human		Kinase Assay

Product Information

Target Protein

BMPR2

Target Family

Kinases/Enzyme Drug Discovery Assays and Products

Target Protein Species

Human

Host Cell Type

INA-6; JJN-3; CHO-K1; HEK293

Target Classification

Kinase Cell Lines

Target Research Area

Cardiovascular Research; Reproductive Research

Related Diseases

Pulmonary Hypertension, Primary, 1 and Pulmonary Venoocclusive Disease 1, Autosomal Dominant. Among its related pathways are Akt Signaling and Signaling by BMP

Gene ID

659

UniProt ID

Q13873

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

Bone morphogenetic protein receptor type 2 is a protein that is made by the BMPR2 gene. The BMPR2 gene is a member of a gene family that was first discovered to control the development and morphology of cartilage and bone. The type 2 bone morphogenetic protein receptor crosses the cell membrane, allowing one end of the protein to be on the cell's exterior and the other end to stay inside. Because of its placement, the protein is able to receive and send signals that aid in a cell's ability to grow, divide, or undergo regulated cell death in response to its surroundings. The ratio of cell division to apoptosis controls the total number of cells in tissues. The customized BMPR2 stable cell line can be used in antibody discovery and development, potential drug candidate screening and signaling pathway researches.

Protocols

Please visit our protocols page.

Customer Reviews

chat Lisa

The BMPR2 cell line has not disappointed. It consistently delivers accurate results, making my work much more impactful. Aug 21 2023

chat Verified Customer

chat Brian

The protocol of BMPR2 KD cell line was straightforward, and the results were consistent. Mar 14 2023

chat Verified Customer

FAQ

Any questions about our products? Please visit our frequently asked questions page.

Published Data

Fig.1 Loss of BMPR2 potentiated activin-induced ALK2 activity.

It was possible to create myeloma cell lines that expressed shRNAs, shCTR (non-targeting), shBMPR2, or shALK1. Using the comparative Ct-method, the expression of BMPR2 mRNA in relation to GAPDH in the cell lines was ascertained in INA-6 and IH-1.

Ref: Olsen, Oddrun Elise, et al. "BMPR2 inhibits activin and BMP signaling via wild-type ALK2." Journal of cell science 131.11 (2018): jcs213512.

Pubmed: 29739878

DOI: 10.1242/jcs.213512

Research Highlights

Compared to patients without BMPR2 mutations, those with PAH and BMPR2 mutations appear at a younger age with a more severe disease and are at a higher risk of dying or requiring a transplant.
Evans, Jonathan DW, et al. "BMPR2 mutations and survival in pulmonary arterial hypertension: an individual participant data meta-analysis." The lancet Respiratory medicine 4.2 (2016): 129-137.
Pubmed: 26795434 DOI: 10.1016/S2213-2600(15)00544-5

This review compiled the most recent research on the molecular underpinnings of BMPR2's roles in BMP signaling as well as the diversity of those activities. Aspects of BMPR2 pathogenic mutations that have been experimentally verified and the associated human disorders will also be covered. These topics are crucial for diagnosis and therapy in clinical settings.
Kim, Myung-Jin, et al. "Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2." BMB reports 50.6 (2017): 308.
Pubmed: 28391780 DOI: 10.5483/bmbrep.2017.50.6.059